✦ LIBER ✦

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

✍ Scribed by Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James H Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill Egorin; Denis Greenslade; Andrew Goetz; Jean L Grem

Book ID: 114106730
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 112 KB
Volume: 30
Category: Article
ISSN: 0093-7754
DOI: 10.1016/s0093-7754(03)00401-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacology of oxaliplatin in solid tum

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

✍ James H Doroshow; Timothy W Synold; David Gandara; Sridhar Mani; Scot C Remick; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Dose-escalating and pharmacological stud

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

✍ Ticiana B. Leal; Scot C. Remick; Chris H. Takimoto; Ramesh K. Ramanathan; Angela 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 397 KB

Merging of the National Cancer Institute

Merging of the National Cancer Institute–funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group

✍ R. Aplenc; B. T. Fisher; Y. S. Huang; Y. Li; T. A. Alonzo; R. B. Gerbing; M. Hal 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB